US approval for Renvela challenger Velphoro
This article was originally published in Scrip
Executive Summary
Velphoro (sucroferric oxyhydroxide) has received US FDA approval for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Velphoro will be launched in the US by Fresenius Medical Care North America in 2014.